Q32 Bio Inc. Share Price

Q32 Bio Inc. Share Price

NASDAQ: QTTB | Micro Cap
$8.88
-$0.21 (-2.31%) Last updated on 30 Oct, 2026 | 01:29 IST
  • Performance
  • Chart
  • Fundamentals
  • Quarterly P&L
  • Annual P&L
  • About
  • Price history
  • FAQs

Q32 Bio Inc. Stock Performance

Open
$9.20
Prev. Close
$9.09
Circuit Range
N/A
Day Range
$8.87 - $9.30
Year Range
$1.92 - $23.38
Volume
15,689
Average Traded
$9.01

Q32 Bio Inc. Share Price Today

As of 30 October 2026, Q32 Bio Inc.'s share price is $8.88. The stock opened at $9.20, compared to its previous close of $9.09. During today's trading session, Q32 Bio Inc.'s share price traded between $8.87 and $9.30, with an average price of $9.09. Over the past 52 weeks, the stock has recorded a high of $23.38 and a low of $1.92. In terms of performance, Q32 Bio Inc.'s share price has risen by 56.89% over the last six months and is up 213.78% on a year-on-year basis.

Q32 Bio Inc. Share Price Chart

Line chart of the Q32 Bio Inc. price trend over the selected period. The price fell overall, ranging from 8.87 to 9.32, ending at 8.88.
$8.87$9.30
L
Show Current Price
H

Q32 Bio Inc. Stock Fundamentals & Key Indicators

Market Cap
$109.23M
PE Ratio (TTM)
7.98
Dividend Yield
0.00%
EPS (TTM)
$1.13
Revenue (TTM)
$53.74B
Return On Equity (TTM)
31.90%
Profit Margin
55.49%
Debt to Equity
0.00
Quarterly Earnings Growth YoY
-21.11%

Q32 Bio Inc. Quarterly Profit & Loss

All figures in USD

ParticularsSep 2025Dec 2025Mar 2026Jun 2026
Revenue$0.00$53.74$0.00$0.00
Net Profit-$7.39$57.73-$7.61-$8.95
Net Profit MarginN/A107.42%N/AN/A
Income ChangeN/A881.19%-113.18%-17.61%

Q32 Bio Inc. Annual Profit & Loss

All figures in USD

Particulars20242025
Revenue$0.00$53.74
Net Profit-$47.73$29.82
Net Profit MarginN/A55.49%
Income ChangeN/A162.48%

About Q32 Bio Inc.

Q32 Bio Inc is a clinical-stage biotechnology company focused on developing novel biologics to restore healthy immune balance in patients with alopecia areata (AA) and other autoimmune and inflammatory diseases driven by immune dysfunction. Its product candidate, bempikibart (ADX 914), is a fully human anti-interleukin 7 receptor alpha (IL-7R) antagonist monoclonal antibody designed to block signaling mediated by interleukin 7 (IL 7) and thymic stromal lymphopoietin (TSLP) and re-regulate adaptive immune function. The company has completed two Phase 2a clinical trials evaluating bempikibart, SIGNAL AA Part A for the treatment of alopecia areata and SIGNAL AD for the treatment of atopic dermatitis (AD).

Q32 Bio Inc. Historical Returns

Share price history by day, with open and close prices and the day's change
MonthOpenCloseChange %
Oct 2026
$8.36
$8.89
+7.82%
Sep 2026
$14.49
$8.25
-48.93%
Aug 2026
$15.06
$16.16
+3.13%
Jul 2026
$12.72
$15.66
+22.77%
Jun 2026
$11.81
$12.76
+15.27%
May 2026
$5.46
$11.07
+95.58%
Apr 2026
$6.61
$5.66
-11.01%
Mar 2026
$4.80
$6.36
+39.17%
Feb 2026
$3.95
$4.57
+15.70%
Jan 2026
$3.28
$3.95
+20.43%
Dec 2025
$4.24
$3.28
+50.46%
Nov 2025
$2.78
$2.18
-22.97%

QTTB Share Price FAQs